



## **Axovant Sciences to Present at the JMP Securities Life Sciences Conference**

June 15, 2016

HAMILTON, Bermuda, June 15, 2016 /PRNewswire/ -- Axovant Sciences Ltd. (NYSE: AXON), a leading clinical-stage biopharmaceutical company focused on the treatment of dementia, today announced an upcoming presentation at the JMP Securities Life Sciences Conference on June 22 at 10:30 a.m. EDT.

A simultaneous webcast can be accessed by visiting the Investors section of [www.axovant.com](http://www.axovant.com) and selecting Events and Presentations. A replay will be available for 30 days following the conference.

### **About Axovant**

Axovant Sciences Ltd. is a leading clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutics for the treatment of dementia. Axovant intends to develop a pipeline of product candidates to comprehensively address the cognitive, functional and behavioral components of dementia and related neurological disorders. Our vision is to become the leading company focused on the treatment of dementia by addressing all forms and aspects of the condition.

To view the original version on PR Newswire, visit: <http://www.prnewswire.com/news-releases/axovant-sciences-to-present-at-the-jmp-securities-life-sciences-conference-300285065.html>

SOURCE Axovant Sciences Ltd.

### **Contact:**

Jonathan Neely  
Head, Investor Relations and Corporate Communications  
Axovant Sciences, Inc.  
(212) 634-9744